pipeline spans multiple therapeutic areas, with a strong emphasis on neuroscience, including treatments for sleep-wake disorders such as narcolepsy and idiopathic hypersomnia. Centessa’s lead programs include orexin receptor 2 agonists designed to regulate the sleep-wake cycle and alleviate symptoms such as excessive daytime sleepiness. In addition to neuroscience, the company is also developing therapies in oncology and other disease areas, aiming to deliver potentially first-in-class or best-in-class treatments that could redefine standards of care.